Stefanos Flindris

Dr. Stefanos Flindris

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2021 in In Vivo
Verified
Journal Article
Closed access
PDF file
SFStefanos Flindris
Stefanos Flindris
NKNikolaos Katsoulas
Nikolaos Katsoulas
AGAnna Goussia
Anna Goussia
ALAndreas Christos Lazaris
Andreas Christos Lazaris
INIordanis Navrozoglou
Iordanis Navrozoglou
ITIrene Thymara
Irene Thymara
Background: The aim of the study was to analyze the expression of nuclear receptor interacting protein 1 (NRIP1) and its partner ligand-dependent nuclear receptor co-repressor (LCOR) in endometrioid endometrial cancer and to investigate their association with estrogen receptor (ER), progesterone receptor (PR), Ki-67, clinicopathological parameters and patient survival. Materials and Methods: Immunohistochemical evaluation was carried out to investigate the subcellular expression of NRIP1 and LCOR in endometrioid endometrial cancer samples. Statistical analysis was used to identify the correlations of NRIP1 and LCOR expression with clinicopathological variables and to estimate the survival rates. Results: Endometrial cancer tissues exhibited higher expression of NRIP1 and LCOR in comparison with the normal tissues. Cytoplasmic LCOR expression was positively associated with ER and PR expression, while cytoplasmic NRIP1 expression was positively associated with ER expression. Moreover, cytoplasmic expression of NRIP1 was positively associated with Ki-67. Conclusion: Our study demonstrated that high cytoplasmic expression of LCOR may predict a longer overall survival of patients with endometrioid endometrial cancer. Patients with tumors expressing low levels of LCOR showed a worse survival compared to those expressing high levels.

2 January 2023 in In Vivo
Verified
Journal Article
Open access
PDF file
AKAgathi Karakosta
Agathi Karakosta
TETheocharis Evangelou
Theocharis Evangelou
SFStefanos Flindris
Stefanos Flindris
ISIoanna Samara
Ioanna Samara
ESEffrosyni Styliara
Effrosyni Styliara
PTPetros Tzimas
Petros Tzimas
Background/Aim: Acute pulmonary embolism during cesarean section is extremely rare and only a limited number of cases have been reported in literature. The aim of this study was to report a case of acute high risk pulmonary embolism during elective cesarean section treated with systemic thrombolysis and discuss the multidisciplinary management in both early recognition and prompt treatment. Case Report: A 39-year-old, G5P2, ASA II parturient presented for repeat cesarean section under general anesthesia. A sudden drop in end-tidal CO2 after placenta delivery combined with significant hemodynamic instability after an uneventful intraoperative course was strongly indicative of pulmonary embolism. Urgent transthoracic ultrasound revealed a sizable thrombus in the inferior vena cava and the right atrium. Thrombolysis was carried out intraoperatively using recombinant tissue plasminogen activator, which was administered under continuous US monitoring until thrombus resolution. This resulted in significant bleeding that was treated in a stepwise manner beginning with implementation of massive transfusion protocol, Bakri balloon placement, and rescue hysterectomy several hours after the event. Follow-up was uneventful and she was discharged on the 12th postoperative day. Conclusion: Though pregnancy is one of the major risk factors of the development of venous thromboembolism, acute intraoperative pulmonary embolism is extremely rare. Specific guidelines for the management of such cases are difficult to issue due to the paucity of relevant data. Thus, an individualized approach by a multidisciplinary team for diagnosis and intervention is mandated.

4 December 2023 in Case Reports in Surgery
Verified
Journal Article
Open access
PDF file
CSChristos Stefanou
Christos Stefanou
SGSpiridon Gkogkos
Spiridon Gkogkos
SFStefanos Flindris
Stefanos Flindris
APApostolis K. Paxinos
Apostolis K. Paxinos
TTThomas Tsiantis Thomas Tsiantis
Thomas Tsiantis Thomas Tsiantis
SSSTEFANOS STEFANOU
STEFANOS STEFANOU
Introduction. The incidence of colonic diverticulosis has risen significantly. Diverticular disease is the most frequent cause of colovesical fistulas, which are uncommon complications of diverticulitis. Clinical signs, such as fecaluria and pneumaturia, are typically required to confirm its presence. Finding the cause of the disease so that the proper therapy can be started is the primary goal of a diagnostic workup rather than observing the fistula tract itself. Case Presentation. We present a 43-year-old man complaining of frequent urinary tract infections for six months. On CT abdomen and pelvis, a colovesical fistula was diagnosed. Surgery was performed, and after the division between the sigmoid colon and the bladder, a sigmoidectomy and an end-to-end colorectal anastomosis were performed. During the surgery, the fistula tract was not detected. The patient was discharged in excellent condition on day six, and the catheter was removed on day 10. Conclusion. In conclusion, as in our case, any patient with a urinary tract infection should be suspected of having this condition, especially if he has persistent symptoms that have not responded to standard medical care. Patients who present with fecaluria, pneumaturia, and other specific symptoms of a colovesicular fistula do not necessarily need a barium enema or cystography to confirm the presence of the fistula.

15 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
Charalampos KarachaliosCharalampos Karachalios
Charalampos Karachalios
ILIlias Liapis
Ilias Liapis
SPStamatios Petousis
Stamatios Petousis
EAEmmanouela Aliki Almperi
Emmanouela Aliki Almperi
CMChrysoula Margioula-Siarkou
Chrysoula Margioula-Siarkou
KDKonstantinos Dinas
Konstantinos Dinas
Malignancies of the female upper reproductive tract, especially endometrial and ovarian cancers, generate a significant burden for women worldwide. The possible etiopathogenetic role of chronic human papillomavirus (HPV) infection in the carcinogenesis of the female upper genital tract is neither clearly established not completely understood. Therefore, we performed a literature review, using the PubMed and SCOPUS electronic databases, of the prevalence of HPV DNA in endometrial, primary fallopian tube, ovarian, and primary peritoneal cancers, as well as uterine sarcomas. The present investigation covered 35 studies from different countries on various continents. Overall, the prevalence of HPV was approximately 15% in all the above cancers. HPV DNA was isolated from 11%, 0%, 0%, and 14% of endometrial carcinomas, uterine sarcomas, primary fallopian tube cancers, and ovarian malignant neoplasms, respectively. No relevant studies on primary peritoneal cancers were retrieved. The predominant HPV strain from tumors of the upper female reproductive tract, regardless of the tumor site, was HPV-16, followed by HPV-18. The HPV DNA identified was exclusively from subtypes HPV-6, HPV-11, HPV-16, HPV-18, and HPV-33, which are responsible for the development of not only cervical cancer, but also condylomata acuminata. The findings of the present review indicate that HPV vaccination might prove to be a useful strategy in the prevention of HPV-related carcinomas of the upper genital tract in women.

30 June 2025
Verified
Journal Article
Open access
SFStefanos Flindris
Stefanos Flindris
GMGeorgios Markozannes
Georgios Markozannes
CMChrysoula Margioula-Siarkou
Chrysoula Margioula-Siarkou
NTNikolaos Tsiaras
Nikolaos Tsiaras
GMGeorgia Margioula-Siarkou
Georgia Margioula-Siarkou
KDKonstantinos Dinas
Konstantinos Dinas
This study evaluated the immunohistochemical expression of IRE1 and PERK in breast cancer and explored their associations with clinicopathologic characteristics and survival outcomes. A cohort of 72 breast cancer specimens and 16 controls was analyzed for IRE1 and PERK expression using immunohistochemistry. Associations with clinicopathological variables, hormone receptor status, tumor markers and survival outcomes were assessed using statistical analyses, including Kaplan-Meier survival curves and Cox proportional hazard models. IRE1 and PERK expression levels were significantly elevated in breast cancer tissues compared to controls (p<0.001). Strong positive correlation was observed between IRE1 and PERK expression (Spearman’s ρ=0.55, p<0.001). High PERK expression was associated with older age (p=0.038) and tumor grade 3 (p=0.042), while high IRE1 expression correlated with advanced TNM stage (p<0.001), estrogen receptor (p=0.031), progesterone receptor (p=0.028), and human epidermal growth factor receptor 2 positivity (p=0.028), as well as increased Ki-67 index (p=0.003), suggesting a more aggressive tumor phenotype. IRE1 expression was significantly associated with sentinel lymph node positivity (p=0.001) but inversely related to axillary lymph node involvement (p=0.031). Multivariate Cox regression analysis revealed that high IRE1 expression [immunoreactivity score (IRS) 5-12] was linked to an increased mortality risk [hazard ratio (HR)=12.19, 95% confidence interval (CI)=0.99-150.35, p=0.05], and high PERK expression (IRS 4-12) was similarly associated with worse survival (HR=12.10, 95%CI=1.16-126.30, p=0.04). Tumor stage was the strongest predictor of mortality (HR=79.89, p<0.01). High IRE1 and PERK expression levels are associated with aggressive tumor characteristics and reduced survival in breast cancer, underscoring the importance of the unfolded protein response in carcinogenesis and disease progression.

Verified
Journal Article
Open access
PDF file
SFStefanos Flindris
Stefanos Flindris
CMChrysoula Margioula-Siarkou
Chrysoula Margioula-Siarkou
CCChristos V. Chalitsios
Christos V. Chalitsios
GMGeorgia Margioula-Siarkou
Georgia Margioula-Siarkou
EAEmmanouela Aliki Almperi
Emmanouela Aliki Almperi
GMGeorgios Markozannes
Georgios Markozannes
The prevalence and prognostic value of programmed death ligand 1 (PD-L1) expression, as a potential biomarker in vulvar squamous cell carcinomas (VSCCs), remain underexplored. We searched the PubMed, Scopus, Embase, and Cochrane Library databases until July 2024 for articles examining PD-L1 expression in VSCCs. Random-effects meta-analyses summarized PD-L1 expression overall and in subgroups by immunohistochemistry antibody type, positivity cutoff, tumor stage, and HPV positivity. Additionally, random-effects meta-analyses summarized the association between PD-L1 positivity and cancer prognosis. We included 26 studies comprising 1912 VSCC cases. The summary PD-L1 positivity rate in tumor cells was 59.9% (95% confidence interval [CI]: 47.7–71.4%; I2 = 96%, n = 26), influenced by the different cutoff thresholds utilized to define PD-L1 positivity. Compared to tumor cells, positivity rates were higher in intratumoral immune cells (75.6%; 95%CI: 52.9–92.5; I2 = 95.4%, n = 6) and peritumoral cells (78.9%; 95%CI: 54.4–95.5%; I2 = 91%, n = 3) but with overlapping 95%CIs. No heterogeneity was observed in the rates by tumor stage or HPV status. Positive PD-L1 expression was associated with worse overall (hazard ratio [HR] = 1.43; 95%CI: 1.06–1.93; I2 = 28.9%, n = 7) and progression-free survival (HR = 1.57; 95%CI: 1.07–2.3; I2 = 38.3%, n = 5). The PD-L1 expression rate in VSCC tumor cells varied across studies, was influenced by differences in immunohistochemical evaluation, and was identified as an unfavorable prognostic factor. Large, prospective, multicenter studies with standardized protocols are crucial to further elucidate the clinical significance of PD-L1 expression in VSCCs.